Work

Abstract PO5-20-04: A Phase II Study of Ribociclib and Endocrine Treatment of Physician’s Choice for Locoregional Recurrent, Resected Hormone Receptor Positive HER2 Negative Breast Cancer (RaPhLRR Study)

Year: 2024

Type: conference-abstract

Source: Cancer Research

DOI: 10.1158/1538-7445.sabcs23-po5-20-04

Authors: Oana Danciu, Nancy Chan, Kari Wisinski, Trish Millard, Kathleen Kemmer, Sneha Phadke, Zhengjia Chen, Ana Cuesta Fernandez, Melanie Clark, Alison Conlin, Coral Omene, Sima Ehsani, Stephanie Dublis, Vijayakrishna K. Gadi

Institutions: New York University, University of Wisconsin–Madison, University of Wisconsin Carbone Cancer Center, University of Virginia, University of Michigan, University of Iowa Hospitals and Clinics, Orlando Health, Rutgers Cancer Institute, University of Arizona, Michigan Medicine

Language: English

Topic: Advanced Breast Cancer Therapies

Subfield: Pulmonary and Respiratory Medicine

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W4396591397

Cites:

Cited by:

Related to: 10